Regeneron Inc.'s fortunes - and its stock - experienced an upswing Monday with the disclosure of a potential $485 million deal focused on its VEGF Trap product candidate with Aventis SA. (BioWorld Today)

Epimmune Inc. reduced its staff by 23 percent and implemented other cost-cutting measures that the company said would give it enough operating funds to pull results from ongoing clinical trials in HIV and cancer. (BioWorld Today)

Entering a research deal with Structural GenomiX Inc. that's intended to speed up the testing of drug leads, OSI Pharmaceuticals Inc. separately agreed to issue $135 million in convertible notes in a private placement. (BioWorld Today)

Just when "IPO" had begun to sound like a code acronym or something from a foreign language, biotechnology's long drought with regard to initial public offerings seems to have ended with an August downpour.